Computational Drug-DDS Engineering · CEREBRO-X | Lecanemab
| Parameter | Value | Method |
|---|---|---|
| ΔG single ligand | -11.00 kcal/mol | LIE approximation |
| ΔG avidity | -8.59 kcal/mol | Bell cooperative binding |
| Receptors engaged | 50 | Geometric model |
| Kd class | Weak (>100nM) | Equilibrium binding |
Ligand-receptor docking uses Linear Interaction Energy (LIE) approximation. Avidity computed via Bell 1978 multi-valent model. Higher avidity = longer residence = more transcytosis events.
Docking affinity → release kinetics correlation
Endosomal escape efficiency vs release rate
Purple bands = sleep (00:00–08:00), 3.5× faster clearance (Xie 2013, Science). ECM binding index 0.74: particles trapped in ECM — extended retention.
DLVO theory: V_total = V_vdW (attraction) + V_EDL (electrostatic repulsion). Threshold 25kT prevents aggregation in blood. Debye length = 0.78 nm (physiological ionic strength).
Illustrative decomposition of the composite score into named per-feature terms (a fixed heuristic formula, not Shapley values from a trained model). Green = positive contribution. Red = negative.
→ No mitigation needed
| Capability Dimension | Score | Modules Active |
|---|---|---|
| BBB Engineering | 85% | ✅ |
| PK Prediction | 95% | ✅ |
| Safety Screening | 90% | ✅ |
| Manufacturing | 85% | ✅ |
| Regulatory (FDA) | 90% | ✅ |
| Clinical Translation | 80% | ✅ |
| IP & Economics | 85% | ✅ |
| Stability | 90% | ✅ |
| Severity | Problem Identified | Evidence | DDS Solution | Expected Outcome |
|---|---|---|---|---|
| HIGH | Poor BBB penetration | Native BBB permeability = 5.3% (threshold: >10%) | liposome with Transferrin surface target | 100.0% BBB crossing -- 19.0x improvement |
| CRITICAL | Large molecular weight -- passive BBB diffusion impossible | MW = 147.1 kDa (Lipinski Rule 5 limit: 500 Da for passive) | liposome encapsulation (75% EE) | Active transcytosis delivers 10.0% paylo |
| Step | Setting |
|---|---|
| Freezing | -50°C @ 1°C/min |
| Primary drying | -32°C, 0.148 mbar |
| Secondary drying | +25°C, 0.05 mbar |
| Tg' safety margin | -2.0°C above Tg' |
| Cake collapse risk | OK: primary drying fixed at Tg |
| pH | Ionized Fraction | Zeta (mV) | State |
|---|---|---|---|
| 4.5 | 0.947 | 36.5 mV | Cationic (endosomal escape mode) |
| 5.5 | 0.640 | 16.6 mV | Cationic (endosomal escape mode) |
| 6.5 | 0.151 | -15.2 mV | Near-neutral (stealth circulation mode) |
| 7.4 | 0.022 | -23.6 mV | Near-neutral (stealth circulation mode) |
| 8.0 | 0.006 | -24.6 mV | Near-neutral (stealth circulation mode) |
Excursion Temperature: -20°C for 4h
Lipid Tm: 42°C
ΔT above Tm: -62.0°C
Leakage rate: 0.000009 /h
Analytical check: Re-test DLS particle size + HPLC drug content before release
FUS + microbubbles open BBB via stable cavitation (MI 0.3-0.5). Inertial cavitation (MI>0.8) = irreversible damage. Carrier injected 5 min before FUS for optimal uptake.
Structural integrity: OK
For Lecanemab, the Top-1 DDS achieved a composite score of 62.1/100 (ACCEPTABLE). Below are the CNS group rollups followed by the FULL 62-principle scoreboard covering all three pipeline classes: A (Surrogate) B (Deep) C (Translational)
| P# | Class | Title | Score | Conf. | Method | Reference |
|---|---|---|---|---|---|---|
| P01 | B | Adversarial Stress-Testing Engine | 68.3 | MODERATE | Mean of 6 stress scenarios (pH4.5, pH2, pH8.5, 42°C, complement, oxidation); each sce | |
| P02 | B | Cross-Species PK Scaling (Allometric) | 60.0 | MODERATE | BW^0.75 scaling + class-specific adjustment | |
| P03 | A | Competitive DDS Landscape Radar | 100.0 | LOW | Novelty = 100 - frequency_of_combo_in_CNS_trials, modified by whether the drug's LogP | |
| P04 | B | Quantum Coherence Transport Model | 50.0 | LOW | MW ≥ 500 Da → tunneling negligible | |
| P05 | A | In-Silico Patient Subgroup Stratifier | 100.0 | MODERATE | % subgroups responding (lower CYP risk = more universal) | |
| P06 | A | Lysosomal Trafficking Predictor | 80.0 | MODERATE | Carrier endosomal_escape ⊕ drug-passive permeation at pH 5.5; drug-passive = LogP-dri | |
| P07 | A | Real-Time Literature Mining (PubMed) | 100.0 | LOW | log-count proxy of literature support | |
| P08 | B | Degradation Kinetics Under Oxidative Stress | 28.0 | MODERATE | Arrhenius k=A·exp(-Ea/RT) for carrier; minus penalties for drug-side oxidation-prone | |
| P09 | A | Digital Pharmacovigilance Engine | 85.0 | MODERATE | 100 - sum(metabolite organ accumulation risks) | |
| P10 | B | LNP Ionization State Predictor | 63.7 | MODERATE | Lipid Henderson-Hasselbalch ionization at endosomal pH 5.5, modulated by drug charge- | |
| P11 | B | Formulation Instability Fingerprint | 100.0 | MODERATE | 100 - sum(weak-bond penalties from SMILES) | |
| P12 | B | CNS Disease-Stage-Aware Dosing | 83.0 | MODERATE | Score = 100·BBB_integrity_factor × (0.4 + 0.6·CNS-MPO/6) + targeting_boost (larger bo | |
| P13 | B | PBPK Digital Twin | 3.4 | MODERATE | AUC_brain/AUC_plasma proxy; 3-compartment surrogate | |
| P14 | A | In-silico Dissolution & Release Profile | 0.0 | MODERATE | t50 from carrier kinetics × drug-membrane partition factor (10^logK_mem); HBD-anchori | |
| P15 | A | Shelf-life & Degradation Predictor | 46.2 | MODERATE | Arrhenius baseline × (0.7 + 0.3·EE) × drug_hydrolysis_factor (0.08 penalty per hydrol | |
| P16 | B | Scale-up & Manufacturability | 20.0 | MODERATE | Scale-readiness × shear-robustness, minus drug-processability penalties (MW, HBD-crys | |
| P17 | A | Nanotoxicity & Immunogenicity Screening | 0.0 | MODERATE | Mean of (hemolysis penalized by drug net+ charge, complement penalized for biologics, | |
| P18 | B | Active Targeting & Receptor Binding | 76.0 | HIGH | Ligand-affinity table × density × drug-compatibility (receptor-pathway-specific drug | |
| P19 | A | QbD - Quality by Design Engine | 100.0 | MODERATE | Fraction of CQAs (size, zeta, EE, PDI, drug-loading) within ICH spec — 5th CQA depend | |
| P20 | A | Cost-Efficiency Engine | 0.0 | LOW | Score = 100 - 3·($/mg estimate, drug+carrier+ligand+API). Drug API cost from stereoce | |
| P21 | C | Pre-IND Regulatory Reports | 0.0 | — | skipped_deep_validation_insufficient | |
| P22 | A | Protein Corona Predictor | 0.0 | MODERATE | 100 × exp(-corona_thickness/10); thickness from carrier (|zeta|, size) + drug-side (L | |
| P23 | B | Dynamic Crystal Polymorphism | 80.0 | MODERATE | 100 - polymorph risk (rot_bonds + H-bond pattern) | |
| P24 | B | Shear-Stress & Scale-Up Collapse | 14.3 | MODERATE | log10(crit_shear/operating_shear) × 30; crit_shear softened by drug-load for lipid ca | |
| P25 | A | Extractables & Leachables | 100.0 | MODERATE | 100 - leachables risk by drug LogP × carrier | |
| P26 | A | Microbiome-Excipient Interactions | 83.0 | MODERATE | 100 - mean_microbiome_degradability(carrier) - drug-side risk (anionic-fraction, pola | |
| P27 | A | Lyophilization Cycle Optimizer | 55.0 | MODERATE | 100 - (|Tg'| - 5) × 1.5 | |
| P28 | A | 3D-Printed Polypill Rheology | 40.0 | MODERATE | Carrier-specific printability index | |
| P29 | B | Biomimetic & Exosome Engineering | 65.0 | MODERATE | Stealth-from-macrophage score; PEG ≥5% boost | |
| P30 | B | QM/MM Stimuli-Responsive Cleavage | 45.0 | MODERATE | Score = 50 × |7.4 - pH_trigger| | |
| P31 | B | In-Silico Biodistribution | 2.0 | MODERATE | brain% = BBB · ligand · size_match · 100; 100 if ≥5% | |
| P32 | C | Automated FTO & IP Evader | 0.0 | — | skipped_deep_validation_insufficient | |
| P33 | B | BBB Quantum Breaker (Trojan-Horse Design) | 58.2 | MODERATE | (0.6·ligand + 0.4·size) × density_factor | |
| P34 | A | DNA Logic Gates & Bio-computing | 15.0 | MODERATE | DNA-based carriers score high | |
| P35 | A | Microgravity Formulation Engine | 100.0 | LOW | Sedimentation-Péclet proxy; smaller = better | |
| P36 | A | Geopolitical Supply-Chain Resilience | 85.0 | MODERATE | Supplier-diversity index by carrier + ligand | |
| P37 | A | Eco-Destructible Pharma | 90.0 | MODERATE | Biodegradability index by carrier class | |
| P38 | B | Glymphatic Clearance Trap | 100.0 | MODERATE | Stokes-Einstein: optimum 80-150 nm | |
| P39 | A | Microglial Activation & Neuroinflammation | 100.0 | MODERATE | 100 - (cationic_charge + carrier_risk - PEG_protection) | |
| P40 | B | Intranasal-to-Brain Delivery | 55.0 | MODERATE | Mucoadhesion + thermo-responsive boost | |
| P41 | B | Exosome Cargo Loading Thermodynamics | 40.0 | LOW | Not an exosome carrier — N/A | |
| P42 | A | Region-Specific Spatiotemporal Navigation | 70.0 | MODERATE | Ligand-region specificity table | |
| P43 | B | FUS-Responsive Nanocarriers | 40.0 | MODERATE | FUS-response by carrier acoustic properties | |
| P44 | B | CNS-Specific PBPK Time-Machine | 4.8 | MODERATE | AUC over 24h therapeutic window proxy | |
| P45 | C | FDA 21 CFR Part 11 Compliance | 0.0 | — | skipped_deep_validation_insufficient | |
| P46 | A | Polypharmacy & DDI Simulator | 100.0 | MODERATE | CYP-inhibition heuristic from SMILES | |
| P47 | B | Free Energy Perturbation (FEP+) | 72.0 | LOW | Vina-like ΔG proxy from MW + LogP (deep mode runs full FEP+) | |
| P48 | A | Off-Target Toxicity & QSAR (50-receptor) | 100.0 | MODERATE | 50-receptor QSAR surrogate (hERG, 5HT2B, AhR risks) | |
| P49 | A | Organ-on-a-Chip Simulator | 80.0 | MODERATE | Microfluidic compatibility (size + PDI) | |
| P50 | B | Cryo-Chain Thermal Excursion Predictor | 71.5 | MODERATE | Distance from -20°C phase transition × 1.3 | |
| P51 | B | Terminal Sterilization Survivability | 50.0 | MODERATE | Carrier gamma-radiation survival (25 kGy) | |
| P52 | A | Continuous Manufacturing Digital Twin | 85.0 | MODERATE | Continuous-process readiness by carrier | |
| P53 | A | Dark Data & Negative Results Vault | 100.0 | MODERATE | Similarity-to-documented-failure | |
| P54 | A | Pharmacogenomic-Guided Targeting | 90.0 | MODERATE | Class-based pharmacogenomic applicability | |
| P55 | C | Automated Grant & NIH Proposal Generator | 0.0 | — | skipped_deep_validation_insufficient | |
| P56 | C | Patentability Score Engine | 0.0 | — | skipped_deep_validation_insufficient | |
| P57 | B | Microfluidics & LNP Synthesis Digital Twin | 90.0 | MODERATE | Microfluidic readiness for size 50-150 nm | |
| P58 | B | Impurity Cascade Predictor | 90.0 | MODERATE | Carrier residual-metals impurity profile | |
| P59 | B | 4D Shape-Shifting Carriers | 30.0 | MODERATE | Stimuli-responsive bonus by release kinetics | |
| P60 | A | Swarm Nanorobotics Intelligence | 15.0 | LOW | Swarm capability (most carriers: no) | |
| P61 | B | Synthetic Clinical Trials & Virtual Humans | 30.6 | MODERATE | Virtual-cohort responder fraction | |
| P62 | A | Biobetter / Supergeneric Generator | 40.0 | LOW | Novelty distance from on-market CNS DDS |
Tf-PEG-Liposome: composite CNS-principle score = 62.1/100 (ACCEPTABLE). Carrier: liposome, size 0.0 nm, ζ +0.0 mV, ligand: Transferrin. Strongest group: G4 Safety (71.0/100); weakest: G8 Translational (0.0/100). Evaluated against all 57 Class A surrogate principles.
Combined score (surrogate pass-through + real physics): 12/28 principles scored PASSED (42.9%). Of these, only 7/28 principles ran independent deep computation (passed 3/7 = 42.9%); the rest re-used their Class-A surrogate score pending a future full-physics HPC run. Cite independent_pct, not pct, as evidence of physics-based validation.
| Principle | Validated | Score | Value | Confidence | Method | Narrative |
|---|---|---|---|---|---|---|
| P01 | ✅ | 68.3 | 68.33 | MODERATE | Full MD stress simulation — surrogate value confirmed (full-physics HPC deferred) | Full MD stress simulation: surrogate score 68.33 PASSED. Full deep simulation requires external HPC. |
| P02 | ✅ | 65.0 | 144.0 | LOW | Resolved clinical half-life (bundle tier 1); Mahmood 2007 exponents shown for reference only (half-l | Clinical t½ = 144.0h (human clinical source, bundle tier 1). Reference allometric exponents (Mahmood 2007) for a genuine animal-to-human ext |
| P04 | ❌ | 50.0 | 50 | LOW | Full QM tunneling (QCElemental + ASE) — surrogate value confirmed (full-physics HPC deferred) | Full QM tunneling (QCElemental + ASE): surrogate score 50 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P08 | ❌ | 28.0 | 28.0 | LOW | Full radical-chain reaction MD — surrogate value confirmed (full-physics HPC deferred) | Full radical-chain reaction MD: surrogate score 28.0 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P10 | ✅ | 63.7 | 63.68 | MODERATE | Constant-pH MD simulation — surrogate value confirmed (full-physics HPC deferred) | Constant-pH MD simulation: surrogate score 63.68 PASSED. Full deep simulation requires external HPC. |
| P11 | ✅ | 100.0 | 100 | MODERATE | DFT bond dissociation energies — surrogate value confirmed (full-physics HPC deferred) | DFT bond dissociation energies: surrogate score 100.0 PASSED. Full deep simulation requires external HPC. |
| P12 | ✅ | 83.0 | 83.0 | MODERATE | Stage-specific PBPK with full BBB physiology — surrogate value confirmed (full-physics HPC deferred) | Stage-specific PBPK with full BBB physiology: surrogate score 83.0 PASSED. Full deep simulation requires external HPC. |
| P13 | ❌ | 26.1 | 0.0131 | MODERATE | 3-compartment PBPK ODE (scipy.integrate.odeint): blood ⇌ brain ⇌ peripheral, 24h time course. k_bb_i | Brain AUC = 0.81 units·h, plasma AUC = 61.60 units·h, ratio = 0.0131. Cmax_brain = 0.06 at t = 1.9h. BELOW THRESHOLD AUC ratio. |
| P16 | ❌ | 20.0 | 20 | LOW | CFD of 1000L bioreactor — surrogate value confirmed (full-physics HPC deferred) | CFD of 1000L bioreactor: surrogate score 20 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P18 | ✅ | 100.0 | -10.5 | HIGH | MM/GBSA-style ΔG estimate from validated ligand-receptor Kd database. Full atomistic docking deferre | Ligand 'transferrin' → receptor 'TfR1', ΔG = -10.5 kcal/mol. STRONG BBB-targeting. |
| P23 | ✅ | 80.0 | 80.0 | MODERATE | CSP via DFT — surrogate value confirmed (full-physics HPC deferred) | CSP via DFT: surrogate score 80.0 PASSED. Full deep simulation requires external HPC. |
| P24 | ❌ | 14.3 | 14.31 | LOW | Full CFD + MD coupling — surrogate value confirmed (full-physics HPC deferred) | Full CFD + MD coupling: surrogate score 14.31 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P29 | ✅ | 65.0 | 65 | MODERATE | Full membrane-fusion MD — surrogate value confirmed (full-physics HPC deferred) | Full membrane-fusion MD: surrogate score 65 PASSED. Full deep simulation requires external HPC. |
| P30 | ❌ | 45.0 | 45.0 | LOW | Full QM/MM (PySCF or ORCA) — surrogate value confirmed (full-physics HPC deferred) | Full QM/MM (PySCF or ORCA): surrogate score 45.0 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P31 | ❌ | 100.0 | 0.1 | MODERATE | 7-organ whole-body distribution with size + charge + ligand-status modifiers. | Brain uptake = 0.10%, liver = 16.3%, spleen = 7.8%. INSUFFICIENT BRAIN UPTAKE. |
| P33 | ❌ | 58.2 | 58.2 | LOW | Atomistic docking + SMD pulling — surrogate value confirmed (full-physics HPC deferred) | Atomistic docking + SMD pulling: surrogate score 58.2 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P38 | ✅ | 99.2 | 12.6 | HIGH | Stokes-Einstein D = k_B·T/(6πηr) at 37°C, η_CSF = 7×10⁻⁴ Pa·s. Brain residence scaled to 50-nm refer | D_CSF = 6.18 µm²/s, brain residence ≈ 12.6h. IDEAL (target 6-48h). |
| P40 | ❌ | 55.0 | 55 | LOW | Full nasal cavity CFD — surrogate value confirmed (full-physics HPC deferred) | Full nasal cavity CFD: surrogate score 55 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P41 | ❌ | 40.0 | 40 | LOW | Full membrane mechanics MD — surrogate value confirmed (full-physics HPC deferred) | Full membrane mechanics MD: surrogate score 40 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P43 | ❌ | 40.0 | 40 | LOW | Full acoustic radiation force MD — surrogate value confirmed (full-physics HPC deferred) | Full acoustic radiation force MD: surrogate score 40 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P44 | ❌ | 0.0 | 0.0 | MODERATE | 4-compartment CNS-PBPK ODE with glymphatic clearance: Blood ⇌ Brain_ECF → CSF → Blood. Stokes-Einste | Therapeutic window = 0.0h (brain ≥ 5% dose). Brain AUC = 5.1, Cmax = 0.29. NEEDS DOSE INCREASE. |
| P47 | ❌ | 73.8 | -6.71 | LOW — LIE approximation only | LIE approximation (fallback — Vina unavailable) | Predicted ΔG_binding = -6.71 kcal/mol (LIE approximation (fallback — Vina unavailable)). MODERATE affinity. |
| P50 | ✅ | 71.5 | 71.5 | MODERATE | Full coarse-grained MD lipid phase transition — surrogate value confirmed (full-physics HPC deferred | Full coarse-grained MD lipid phase transition: surrogate score 71.5 PASSED. Full deep simulation requires external HPC. |
| P51 | ❌ | 50.0 | 50 | LOW | Full radical-chain damage MD — surrogate value confirmed (full-physics HPC deferred) | Full radical-chain damage MD: surrogate score 50 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P57 | ✅ | 90.0 | 90 | MODERATE | Full CFD of mixer geometry — surrogate value confirmed (full-physics HPC deferred) | Full CFD of mixer geometry: surrogate score 90 PASSED. Full deep simulation requires external HPC. |
| P58 | ✅ | 90.0 | 90 | MODERATE | Full QM/MM cascade simulation — surrogate value confirmed (full-physics HPC deferred) | Full QM/MM cascade simulation: surrogate score 90 PASSED. Full deep simulation requires external HPC. |
| P59 | ❌ | 30.0 | 30 | LOW | Full coarse-grained MD morphological transition — surrogate value confirmed (full-physics HPC deferr | Full coarse-grained MD morphological transition: surrogate score 30 NEEDS REVIEW. Full deep simulation requires external HPC. |
| P61 | ❌ | 30.6 | 31.0 | LOW | Full Monte-Carlo population PBPK — surrogate value confirmed (full-physics HPC deferred) | Full Monte-Carlo population PBPK: surrogate score 30.6 NEEDS REVIEW. Full deep simulation requires external HPC. |
Translational outputs for Lecanemab's validated Top-1 DDS. These are NOT used for ranking — they are administrative deliverables triggered only AFTER deep physics validation passes.
Deep validation passed only 12/28 principles. Translational deliverables withheld until a higher-ranked DDS passes deep validation.
Deep validation passed only 12/28 principles. Translational deliverables withheld until a higher-ranked DDS passes deep validation.
Deep validation passed only 12/28 principles. Translational deliverables withheld until a higher-ranked DDS passes deep validation.
Deep validation passed only 12/28 principles. Translational deliverables withheld until a higher-ranked DDS passes deep validation.
Deep validation passed only 12/28 principles. Translational deliverables withheld until a higher-ranked DDS passes deep validation.
For Lecanemab: each candidate DDS that was tried in the Class B deep validation phase. If the Top-1 fails the 70% threshold, we fall back to Top-2, then Top-3 — with explicit reasons recorded.
| Rank | DDS | Surrogate | Verdict | Promoted? | Failure Reason | Transition Reason |
|---|---|---|---|---|---|---|
| #1 | Tf-PEG-Liposome | 62.14 | FAILED 42.9% (12/28) |
— | Deep validation FAILED: only 12/28 principles validated (42.9%, threshold 70%). Critical failures: P04, P08, P13, P16, P24. | Falling back to rank #2 because deep physics showed insufficient evidence for this DDS. |
| #2 | RVG29-Liposome-pH | 61.79 | FAILED 42.9% (12/28) |
— | Deep validation FAILED: only 12/28 principles validated (42.9%, threshold 70%). Critical failures: P04, P08, P13, P16, P24. | Falling back to rank #3 because deep physics showed insufficient evidence for this DDS. |
| #3 | AAV9-vector | 53.65 | FAILED 35.7% (10/28) |
— | Deep validation FAILED: only 10/28 principles validated (35.7%, threshold 70%). Critical failures: P04, P08, P13, P16, P18. | No more candidates in Top-3 — reverting to rank #1 and reporting with FAILED verdict. Researcher should reformulate. |